Dressler F A, Craig W R, Castello R, Labovitz A J
Department of Internal Medicine and Pathology, Saint Louis University Health Sciences Center, Missouri 63110, USA.
J Am Coll Cardiol. 1998 Jan;31(1):134-8. doi: 10.1016/s0735-1097(97)00449-x.
We sought to determine the influence of plaque morphology and warfarin anticoagulation on the risk of recurrent emboli in patients with mobile aortic atheroma.
An epidemiologic link between aortic atheroma and systemic emboli has been described both in pathologic and transesophageal studies. Likewise, a few studies have found an increased incidence of recurrent emboli in these patients. The therapeutic implications of these findings has not been studied.
Thirty-one patients presenting with a systemic embolic event and found to have mobile aortic atheroma were studied. The height, width and area of both immobile and mobile portions of atheroma were quantitated. The dimensions of the mobile component was used to define three groups: small, intermediate and large mobile atheroma. The patients were followed up by means of telephone interview and clinical records, with emphasis on anticoagulant use and recurrent embolic or vascular events.
Patients not receiving warfarin had a higher incidence of vascular events (45% vs. 5%, p = 0.006). Stroke occurred in 27% of these patients and in none of those treated with warfarin. The annual incidence of stroke in patients not taking warfarin was 0.32. Myocardial infarction occurred in 18% of patients also in this group. Taken together, the risk of myocardial infarction or stroke was significantly increased in this group (p = 0.001). Forty-seven percent of patients with small, mobile atheroma did not receive warfarin. Recurrent stroke occurred in 38% of these patients, representing an annual incidence of 0.61. There were no strokes in patients with small, mobile atheroma treated with warfarin (p = 0.04). Likewise, none of the patients with intermediate or large mobile atheroma had a stroke during follow-up. Only three of these patients had not been taking warfarin.
Patients presenting with systemic emboli and found to have mobile aortic atheroma on transesophageal echocardiography have a high incidence of recurrent vascular events. Warfarin is efficacious in preventing stroke in this population. The dimension of the mobile component of atheroma should not be used to determine the need for anticoagulation.
我们试图确定斑块形态和华法林抗凝治疗对活动性主动脉粥样硬化患者复发性栓塞风险的影响。
在病理学和经食管研究中均已描述主动脉粥样硬化与系统性栓塞之间的流行病学联系。同样,一些研究发现这些患者复发性栓塞的发生率增加。这些发现的治疗意义尚未得到研究。
对31例发生系统性栓塞事件且发现有活动性主动脉粥样硬化的患者进行研究。对粥样硬化的固定和活动部分的高度、宽度和面积进行定量。活动成分的尺寸用于定义三组:小、中、大活动性粥样硬化。通过电话访谈和临床记录对患者进行随访,重点关注抗凝剂的使用以及复发性栓塞或血管事件。
未接受华法林治疗的患者血管事件发生率更高(45%对5%,p = 0.006)。这些患者中有27%发生中风,而接受华法林治疗的患者中无一例发生中风。未服用华法林的患者中风年发生率为0.32。该组患者中有18%发生心肌梗死。总体而言,该组患者发生心肌梗死或中风的风险显著增加(p = 0.001)。47%的小活动性粥样硬化患者未接受华法林治疗。这些患者中有38%发生复发性中风,年发生率为0.61。接受华法林治疗的小活动性粥样硬化患者中无一例发生中风(p = 0.04)。同样,中、大活动性粥样硬化患者在随访期间均未发生中风。这些患者中只有3例未服用华法林。
经食管超声心动图检查发现有活动性主动脉粥样硬化且发生系统性栓塞的患者复发性血管事件发生率很高。华法林对预防该人群的中风有效。不应使用粥样硬化活动成分的尺寸来确定抗凝治疗的必要性。